Singapore-based Biotech company ImmunoScape has announced that it has raised $11 million (SGD $14.8 million) in a financing round. The round was led by Anzu Partners with participation from the University of Tokyo Edge Capital (UTEC) in Japan and NPR Holdings in Indonesia.
ImmunoScape’s work has provided some deep insights into T-cells of the human immune system and the company has done some promising work in COVID-19 related programs on multiple continents.
“To deliver on the promise of individualized medicine for cancer, the biopharma industry desperately needs more insight into every patient's unique immune system. ImmunoScape can deliver this, and we are delighted to support them,” said David Michael, Managing Partner of Anzu Partners.
The company is currently focussing on understanding the T-cell immune response to COVID-19 immunity to leverage vaccine design. ImmunoScape co-founder and Chief Operating Officer Dr. Alessandra Nardin said, “In global collaborations with Massachusetts General Hospital, University of Parma (Italy), and Duke-NUS, we are evaluating COVID-19 patients and recovered individuals. We are building a large data set on human T-cell response to COVID-19, in an effort to develop new therapies and better vaccines with our partners.”
The company is supported by Singapore’s Agency for Science and Research and has deep experience in assessing T-cell immune response to dengue, hepatitis B, and other viruses. Its core mission has been to develop advanced immunotherapies for cancer and it is something ImmunoScape continues to offer promise in.
Indonesia's GoTo Group raises over $1.3 billion ahead of IPO
Diageo to build a $75 million distillery to produce its first Chinese single-malt whisky
ProLogium Technology secures $326 million to expand global EV battery production capability
Indian online insurer Acko raises $255 million in expansion drive, hits unicorn status
Chinese ride-sharing platform T3 raises $1.2 billion in Series A funding to expand
© 2021 CIO Bulletin. All rights reserved.